A 4-week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A 4-week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs AZD 4818 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms TOP
  • Most Recent Events

    • 15 Apr 2010 Results were published in Respiratory Medicine.
    • 12 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society.
    • 23 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top